ASX:RCE – China Patent Acceptance Strengthens Global Anti-Infective Portfolio
Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives technology, extending protection until 2041 and expanding access…
Australia/USA – Mesoblast Secures FDA Orphan-Drug Exclusivity for RYONCIL
Regulatory Achievement Overview Mesoblast has obtained seven years of orphan-drug exclusive approval from FDA for RYONCIL® (remestemcel-L) in treating steroid-refractory…
